Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Brett Schroeder, Zula Li, Lee D Cranmer, Robin L Jones & Seth M Pollack. (2016) Targeting gastrointestinal stromal tumors: the role of regorafenib. OncoTargets and Therapy 9, pages 3009-3016.
Read now
Read now
Articles from other publishers (11)
Youssif Abo Elseud, Amrou Shaaban, Asit Mohanty & Jasem Albarrak. (2021) Safety and tolerability of regorafenib: a real-life experience. Journal of Gastrointestinal Cancer 53:1, pages 187-191.
Crossref
Crossref
Shengfu Wang, Chunyan Wang, Xiao Wang, Xiang Wang, Lina Huang, Jiajie Kuai, Wei Wei, Xiaorong Lu & Shangxue Yan. (2021) Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors. Cancer Chemotherapy and Pharmacology 88:5, pages 795-804.
Crossref
Crossref
Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt & Patrick Schӧffski. (2020) Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. British Journal of Cancer 122:8, pages 1158-1165.
Crossref
Crossref
Rebecca Shatsky, Barbara A. Parker, Nam Q. Bui, Teresa Helsten, Richard B. Schwab, Sarah G Boles & Razelle Kurzrock. (2019) Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Molecular Cancer Therapeutics 18:5, pages 1001-1011.
Crossref
Crossref
Yuanyuan Shan, Binghe Wang & Jie Zhang. (2018) New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. Medicinal Research Reviews 38:5, pages 1674-1705.
Crossref
Crossref
J. Aguilar-Company, M. Fernández-Ruiz, R. García-Campelo, A.C. Garrido-Castro & I. Ruiz-Camps. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). Clinical Microbiology and Infection 24, pages S41-S52.
Crossref
Crossref
Adriana Ziółkowska, Katarzyna Glińska, Sylwia Szymańska & Sergiusz Jóźwiak. (2017) Nerwiakowłókniakowatość typu 1 – choroba wymagająca wielodyscyplinarnej opieki specjalistycznej. Pediatria Polska 92:3, pages 294-302.
Crossref
Crossref
J. Rick Turner, Dilip R. Karnad & Snehal KothariJ. Rick Turner, Dilip R. Karnad & Snehal Kothari. 2017. Cardiovascular Safety in Drug Development and Therapeutic Use. Cardiovascular Safety in Drug Development and Therapeutic Use
201
221
.
Soojung LeeJudee Grace E. NemeñoJeong Ik Lee. (2016) Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. Tissue Engineering Part B: Reviews 22:5, pages 341-357.
Crossref
Crossref
Boris Pinchuk, Rebecca Horbert, Alexander Döbber, Lydia Kuhl & Christian Peifer. (2016) Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors. Molecules 21:5, pages 570.
Crossref
Crossref
Yannis Metaxas, Georgios Oikonomopoulos & George Pentheroudakis. (2016) Update on clinical research and state of the art management of patients with advanced sarcomas and GIST. ESMO Open 1:3, pages e000065.
Crossref
Crossref